Asia-Pacific In-Vitro Diagnostics Market Forecast to 2030

Name: Asia-Pacific In-Vitro Diagnostics Market Forecast to 2030
Creator: Next Move Strategy Consulting
Published: 2025-08-14T20:00:00-04:00
License: https://www.nextmsc.com/privacy-policy

About Report

Download Now

Asia-Pacific In-Vitro Diagnostics Market by Type (Reagents, Instruments, and Software & Services), by Technique (Immunodiagnostics, Hematology, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Other IVD Techniques), by Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and Others) – Opportunity Analysis and Industry Forecast, 2024–2030

Download PDF

Speak to Our Analyst

Asia-Pacific In-Vitro Diagnostics Market Overview

The Asia-Pacific In-Vitro Diagnostics Market size was valued at USD 27.51 billion in 2023, and is predicted to reach USD 40.79 billion by 2030, at a CAGR of 5.4% from 2024 to 2030. In-vitro diagnostics (IVD) refers to a wide range of medical tests conducted on samples of bodily fluids, tissues, or cells outside of the body to diagnose diseases, monitor therapy, and assess overall health conditions. IVD tests are performed in laboratory settings using various techniques and technologies, including immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology.

These tests enable early detection of diseases, allowing for timely intervention and treatment initiation. By providing rapid and accurate results, IVD tests facilitate personalized medicine, guiding tailored treatment approaches based on individual patient characteristics. Also, immunoassay experiments provide valuable insights into biological systems, enabling scientists and researchers to make significant contributions to fields such as medicine, biotechnology, and pharmacology. They serve as essential tools for understanding fundamental biological processes and developing innovative solutions to address health challenges.

Increasing Chronic Disease Prevalence in Asia-Pacific Drives Significant Market Growth

The high prevalence of chronic diseases, particularly cardiovascular diseases and cancer, highlights the crucial need for immunodiagnostic tests that enable early detection and continuous monitoring. This growing demand is further amplified by substantial healthcare spending in the region, which strengthens healthcare infrastructure and increases access to diagnostic services.

Enhanced financial resources allow for the adoption of advanced diagnostic technologies, improving the ability to diagnose and manage these chronic conditions effectively. Consequently, the combination of rising chronic disease rates and increased healthcare expenditure is driving significant growth in the in-vitro diagnostic market in the Asia-Pacific region.

Technological Advancements Drive the Growth of Market in Asia-Pacific

Technological innovations by market players are significantly enhancing diagnostic capabilities, leading to the expanding Asia-Pacific in-vitro diagnostics market demand. These advancements enable more accurate, efficient, and faster diagnostic tests, which are essential for early detection and effective management of diseases.

Coupled with evolving healthcare needs and substantial investments in healthcare infrastructure, the region is witnessing a surge in demand for advanced diagnostic solutions. This creates significant growth opportunities for the in-vitro diagnostics market, as healthcare providers adopt these cutting-edge technologies to improve patient outcomes and meet the rising demand for high-quality clinical diagnostic services.

High Research, Development, and Regulatory Approval Costs Hinder the Market Growth

High costs associated with research, development, and regulatory approval are significant factors restraining the Asia-Pacific IVD market expansion. Operating within this sector necessitates significant financial investment for companies to navigate the complex landscape of research and development.

This investment often encompasses extensive clinical trials, laboratory testing, and product refinement to guarantee accuracy and reliability. Additionally, obtaining regulatory approvals from agencies such as the FDA requires strict adherence to stringent standards, further compounding the financial burden. This financial constraint can discourage potential adopters from market expansion.

Introduction of Point-of-Care Testing Solutions in IVD Creates Opportunity

Point-of-care testing (POCT) is poised to significantly drive the Asia-Pacific in-vitro diagnostics market demand in the forthcoming years. POCT serves as a valuable complement to laboratory testing, especially in situations where immediate results are crucial, such as emergency departments, ambulances, and remote healthcare settings.

With POCT technologies offering rapid tests for infectious diseases, cardiac markers, glucose monitoring, pregnancy testing, and more, healthcare providers can quickly assess patients' conditions and make timely treatment decisions.

By integrating POCT with traditional IVD, healthcare providers can enhance their diagnostic capabilities, delivering more efficient and patient-centered care. This integration streamlines workflows, allowing for faster diagnosis and treatment initiation, ultimately leading to improved patient outcomes.

China Dominates the Asia-Pacific In-Vitro Diagnostics Market Share

The prevalence of chronic diseases significantly drives the growth of the in-vitro diagnostics market in China. According to National Institutes of Health, in China, there are higher rates of cardiovascular disease, cancer, chronic respiratory disease, and diabetes compared to regions with similar social development levels. These non-communicable diseases are responsible for 88.5% of all deaths and contribute to 84.9% of the disease burden, as measured by disability-adjusted life years (DALYs).

As these conditions continue to rise, there is an increasing demand for accurate and efficient diagnostic solutions to effectively manage and monitor patient health. IVD tests play a crucial role in this landscape by enabling early disease detection, personalized treatment strategies, and ongoing disease monitoring.

Singapore to Witness Substantial Growth in the Market

Increased healthcare expenditure in Singapore serves as a significant factor for the growth of the in-vitro diagnostics market. According to World Trade Administration, the Singapore National Health Expenditure is projected to reach around USD 44 billion by 2030 to address both short and long-term infrastructure needs and to provide support for healthcare provisions and subsidies for low-income individuals. This investment creates opportunities for the adoption of advanced in-vitro diagnostics technologies, leading to improved disease detection, monitoring, and personalized treatment options.

Competitive Landscape

The promising players operating in the Asia-Pacific in-vitro diagnostics industry include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.

Asia-Pacific In-Vitro Diagnostics Market Key Segments

By Product & Service

Reagents & Consumables
- Clinical Chemistry Reagents
- Immunoassay Reagents (ELISA/CLIA)
- Molecular Master Mixes
- Hematology Controls
Instruments & Devices
- Chemistry Analyzers
- Immunoassay Systems
- Molecular Thermocyclers/Sequencers
- Hematology Analyzers
- POC Devices
Software & Services
- LIS, Data Analytics
- CRO/Testing Services

By Technique

Clinical Chemistry
- Metabolites
- Electrolytes
- Enzymes
Immunoassays
- ELISA / CLIA / CMIA
- Lateral-flow Rapid Tests
- Immunofluorescence
Molecular Diagnostics
- PCR
- Isothermal NAAT
- NGS
- In-situ Hybridization
Hematology & Coagulation
- CBC Analyzers
- Coagulation Panels
Microbiology
- Culture & Sensitivity
- MALDI-TOF
- Molecular ID
Urinalysis & Body Fluids
Other Techniques

By Testing Site / Channel

Central & Reference Laboratories
Hospital & Physician Labs
Point-of-Care & Retail
Home & Self-Testing

By Application

Infectious Diseases
Oncology
Cardiovascular Health
Endocrinology & Diabetes
Nephrology
Genetic & Prenatal Testing
Autoimmune Disorders
Drug Monitoring & Toxicology
Blood Screening & Typing
Other Indications

By Country

China
India
South Korea
Australia
Indonesia
Singapore
Taiwan
Thailand
Rest of Asia-Pacific

Key Players

Roche Holding AG
Abbott Laboratories
Thermo Fisher Scientific Inc.
Danaher Corporation
Becton, Dickinson and Company
Siemens Healthineers AG
bioMérieux SA
Sysmex Corporation
QIAGEN N.V.
Bio-Rad Laboratories, Inc.

Report Scope and Segmentation

Parameters	Details
Market Size Value in 2023	USD 27.51 billion
Revenue Forecast in 2030	USD 40.79 billion
Value Growth Rate	CAGR of 5.4% from 2024 to 2030
Analysis Period	2023–2030
Base Year Considered	2023
Forecast Period	2024–2030
Market Size Estimation	Billion (USD)
Growth Factors	Increasing Chronic Disease Prevalence in Asia-Pacific Drives Significant Market Growth. Technological Advancement Drives the Growth of Asia-Pacific IVD Market.
Companies Profiled	10
Countries Covered	8
Customization Scope	Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs.

About the Author

Sikha Haritwal is an assistant manager with strong expertise in market research, data analysis, and cross-functional coordination. She plays a key role in leading complex research initiatives, strengthening analytical rigor, and enabling data-driven decision-making across teams. Known for her leadership mindset and structured problem-solving approach, she supports process improvement, enhances operational efficiency, and contributes to building scalable frameworks that drive long-term strategic outcomes and organizational effectiveness.

About the Reviewer

Supradip Baul is an accomplished business consultant and strategist with over a decade of rich experience in market intelligence, strategy, technology, and business transformation. His work has included rigorous qualitative and quantitative analysis across multiple industries, helping clients shape investment decisions and long-term roadmaps. Earlier in his career, he was associated with Gartner, where he contributed to industry-leading reports and market share analyses. He has worked with leading global companies and holds an MBA with a dual specialization in Marketing and Finance.

1. 1.1 REPORT DESCRIPTION
2. 1.2 RESEARCH METHODOLOGY
3. 1. 1.2.1 SECONDARY RESEARCH
  2. 1.2.2 DATA ANALYSIS FRAMEWORK
  3. 1.2.3 MARKET SIZE ESTIMATION
  4. 1.2.4 FORECASTING
  5. 1.2.5 PRIMARY RESEARCH AND DATA VALIDATION

1. 2.1. MARKET SNAPSHOT, 2023 - 2030, MILLION USD

1. 3.1 BARGAINING POWER OF SUPPLIERS
2. 3.2 BARGAINING POWER OF BUYERS
3. 3.3 DEGREE OF COMPETITION
4. 3.4 THREAT OF SUBSTITUTE
5. 3.5 THREAT OF NEW ENTRANTS

1. 4.1 MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2023

1. 5.1 GROWTH DRIVERS
2. 1. 5.1.1 DRIVER 1
  2. 5.1.2 DRIVER 2
  3. 5.1.3 DRIVER 3
  4. 5.1.4 DRIVER 4
3. 5.2 CHALLENGES
4. 1. 5.2.1 CHALLENGE 1
  2. 5.2.2 CHALLENGE 2
  3. 5.2.3 CHALLENGE 3
  4. 5.2.4 CHALLENGE 4
5. 5.3 OPPORTUNITIES
6. 1. 5.3.1 OPPORTUNITY 1
  2. 5.3.2 OPPORTUNITY 2

1. 6.1 OVERVIEW
2. 6.2 REAGENTS
3. 1. 6.2.1 REAGENTS MARKET, BY COUNTRY
4. 6.3 INSTRUMENTS
5. 1. 6.3.1 INSTRUMENTS MARKET, BY COUNTRY
6. 6.4 SOFTWARE AND SERVICES
7. 1. 6.4.1 SOFTWARE AND SERVICES MARKET, BY COUNTRY

1. 7.1 OVERVIEW
2. 7.2 IMMUNODIAGNOSTICS
3. 1. 7.2.1 IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE
  2. 1. 7.2.1.1 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET, BY COUNTRY
    2. 7.2.1.2 RAPID TESTS MARKET, BY COUNTRY
    3. 7.2.1.3 CHEMILUMINESCENCE IMMUNOASSAY (CLIA) MARKET, BY COUNTRY
    4. 7.2.1.4 ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT) MARKET, BY COUNTRY
    5. 7.2.1.5 RADIOIMMUNOASSAY (RIA) MARKET, BY COUNTRY
    6. 7.2.1.6 WESTERN BLOT MARKET, BY COUNTRY
  3. 7.2.2 IMMUNODIAGNOSTICS MARKET, BY COUNTRY
4. 7.3 HEMATOLOGY
5. 1. 7.3.1 HEMATOLOGY MARKET, BY COUNTRY
6. 7.4 MOLECULAR DIAGNOSTICS
7. 1. 7.4.1 MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE
  2. 1. 7.4.1.1 PCR MARKET, BY COUNTRY
    2. 7.4.1.2 INAAT MARKET, BY COUNTRY
    3. 7.4.1.3 HYBRIDIZATION MARKET, BY COUNTRY
    4. 7.4.1.4 DNA DIAGNOSTICS MARKET, BY COUNTRY
    5. 7.4.1.5 MICROARRAY MARKET, BY COUNTRY
    6. 7.4.1.6 OTHER MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY
  3. 7.4.2 MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY
8. 7.5 TISSUE DIAGNOSTICS
9. 1. 7.5.1 TISSUE DIAGNOSTICS MARKET, BY COUNTRY
10. 7.6 CLINICAL CHEMISTRY
11. 1. 7.6.1 CLINICAL CHEMISTRY MARKET, BY TECHNIQUE
  2. 1. 7.6.1.1 BASIC METABOLIC PANEL MARKET, BY COUNTRY
    2. 7.6.1.2 LIVER PANEL MARKET, BY COUNTRY
    3. 7.6.1.3 RENAL PROFILE MARKET, BY COUNTRY
    4. 7.6.1.4 LIPID PROFILE MARKET, BY COUNTRY
    5. 7.6.1.5 THYROID FUNCTION PANEL MARKET, BY COUNTRY
    6. 7.6.1.6 ELECTROLYTE PANEL MARKET, BY COUNTRY
    7. 7.6.1.7 SPECIALITY CHEMICALS MARKET, BY COUNTRY
  3. 7.6.2 CLINICAL CHEMISTRY MARKET, BY COUNTRY
12. 7.7 OTHER IVD TECHNIQUES
13. 1. 7.7.1 OTHER IVD TECHNIQUES MARKET, BY COUNTRY

1. 8.1 OVERVIEW
2. 8.2 INFECTIOUS DISEASES
3. 1. 8.2.1 INFECTIOUS DISEASES MARKET, BY COUNTRY
4. 8.3 CANCER
5. 1. 8.3.1 CANCER MARKET, BY COUNTRY
6. 8.4 CARDIAC DISEASES
7. 1. 8.4.1 CARDIAC DISEASES MARKET, BY COUNTRY
8. 8.5 IMMUNE SYSTEM DISORDERS
9. 1. 8.5.1 IMMUNE SYSTEM DISORDERS MARKET, BY COUNTRY
10. 8.6 NEPHROLOGICAL DISEASES
11. 1. 8.6.1 NEPHROLOGICAL DISEASES MARKET, BY COUNTRY
12. 8.7 GASTROINTESTINAL DISEASES
13. 1. 8.7.1 GASTROINTESTINAL DISEASES MARKET, BY COUNTRY
14. 8.8 OTHERS
15. 1. 8.8.1 OTHERS MARKET, BY COUNTRY

1. 9.1 OVERVIEW
2. 9.2 STAND ALONE LABORATORY
3. 1. 9.2.1 STAND ALONE LABORATORY MARKET, BY COUNTRY
4. 9.3 HOSPITALS
5. 1. 9.3.1 HOSPITALS MARKET, BY COUNTRY
6. 9.4 ACADEMICS AND MEDICAL SCHOOLS
7. 1. 9.4.1 ACADEMICS AND MEDICAL SCHOOLS MARKET, BY COUNTRY
8. 9.5 POINT OF CARE TESTING
9. 1. 9.5.1 POINT OF CARE TESTING MARKET, BY COUNTRY
10. 9.6 OTHER END USERS
11. 1. 9.6.1 OTHER END USERS MARKET, BY COUNTRY

1. 10.1 OVERVIEW
2. 10.2 AUSTRALIA
3. 1. 10.2.1 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.2.2 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.2.3 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.2.4 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END USER
4. 10.3 CHINA
5. 1. 10.3.1 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.3.2 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.3.3 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.3.4 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END USER
6. 10.4 INDIA
7. 1. 10.4.1 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.4.2 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.4.3 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.4.4 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END USER
8. 10.5 JAPAN
9. 1. 10.5.1 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.5.2 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.5.3 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.5.4 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END USER
10. 10.6 SOUTH KOREA
11. 1. 10.6.1 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.6.2 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.6.3 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.6.4 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END USER
12. 10.7 INDONESIA
13. 1. 10.7.1 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.7.2 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.7.3 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.7.4 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END USER
14. 10.8 SINGAPORE
15. 1. 10.8.1 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.8.2 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.8.3 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.8.4 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END USER
16. 10.9 TAIWAN
17. 1. 10.9.1 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.9.2 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.9.3 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.9.4 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END USER
18. 10.10 THAILAND
19. 1. 10.10.1 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.10.2 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.10.3 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.10.4 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END USER
20. 10.11 REST OF ASIA-PACIFIC
21. 1. 10.11.1 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.11.2 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.11.3 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.11.4 ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END USER

1. 11.1 ROCHE HOLDING AG
2. 1. 11.1.1 COMPANY OVERVIEW
  2. 11.1.2 COMPANY SNAPSHOT
  3. 11.1.3 OPERATING BUSINESS SEGMENTS
  4. 11.1.4 PRODUCT PORTFOLIO
  5. 11.1.5 BUSINESS PERFORMANCE
  6. 11.1.6 BUSINESS SEGMENTS
  7. 11.1.7 GEOGRAPHIC SEGMENTS
  8. 11.1.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.1.9 PRIMARY MARKET COMPETITORS
3. 11.2 ABBOTT LABORATORIES
4. 1. 11.2.1 COMPANY OVERVIEW
  2. 11.2.2 COMPANY SNAPSHOT
  3. 11.2.3 OPERATING BUSINESS SEGMENTS
  4. 11.2.4 PRODUCT PORTFOLIO
  5. 11.2.5 BUSINESS PERFORMANCE
  6. 11.2.6 BUSINESS SEGMENTS
  7. 11.2.7 GEOGRAPHIC SEGMENTS
  8. 11.2.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.2.9 PRIMARY MARKET COMPETITORS
5. 11.3 THERMO FISHER SCIENTIFIC INC.
6. 1. 11.3.1 COMPANY OVERVIEW
  2. 11.3.2 COMPANY SNAPSHOT
  3. 11.3.3 OPERATING BUSINESS SEGMENTS
  4. 11.3.4 PRODUCT PORTFOLIO
  5. 11.3.5 BUSINESS PERFORMANCE
  6. 11.3.6 BUSINESS SEGMENTS
  7. 11.3.7 GEOGRAPHIC SEGMENTS
  8. 11.3.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.3.9 PRIMARY MARKET COMPETITORS
7. 11.4 DANAHER CORPORATION
8. 1. 11.4.1 COMPANY OVERVIEW
  2. 11.4.2 COMPANY SNAPSHOT
  3. 11.4.3 OPERATING BUSINESS SEGMENTS
  4. 11.4.4 PRODUCT PORTFOLIO
  5. 11.4.5 BUSINESS PERFORMANCE
  6. 11.4.6 BUSINESS SEGMENTS
  7. 11.4.7 GEOGRAPHIC SEGMENTS
  8. 11.4.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.4.9 PRIMARY MARKET COMPETITORS
9. 11.5 BECTON, DICKINSON AND COMPANY
10. 1. 11.5.1 COMPANY OVERVIEW
  2. 11.5.2 COMPANY SNAPSHOT
  3. 11.5.3 OPERATING BUSINESS SEGMENTS
  4. 11.5.4 PRODUCT PORTFOLIO
  5. 11.5.5 BUSINESS PERFORMANCE
  6. 11.5.6 BUSINESS SEGMENTS
  7. 11.5.7 GEOGRAPHIC SEGMENTS
  8. 11.5.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.5.9 PRIMARY MARKET COMPETITORS
11. 11.6 SIEMENS HEALTHINEERS AG
12. 1. 11.6.1 COMPANY OVERVIEW
  2. 11.6.2 COMPANY SNAPSHOT
  3. 11.6.3 OPERATING BUSINESS SEGMENTS
  4. 11.6.4 PRODUCT PORTFOLIO
  5. 11.6.5 BUSINESS PERFORMANCE
  6. 11.6.6 BUSINESS SEGMENTS
  7. 11.6.7 GEOGRAPHIC SEGMENTS
  8. 11.6.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.6.9 PRIMARY MARKET COMPETITORS
13. 11.7 BIOMÉRIEUX SA
14. 1. 11.7.1 COMPANY OVERVIEW
  2. 11.7.2 COMPANY SNAPSHOT
  3. 11.7.3 OPERATING BUSINESS SEGMENTS
  4. 11.7.4 PRODUCT PORTFOLIO
  5. 11.7.5 BUSINESS PERFORMANCE
  6. 11.7.6 BUSINESS SEGMENTS
  7. 11.7.7 GEOGRAPHIC SEGMENTS
  8. 11.7.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.7.9 PRIMARY MARKET COMPETITORS
15. 11.8 SYSMEX CORPORATION
16. 1. 11.8.1 COMPANY OVERVIEW
  2. 11.8.2 COMPANY SNAPSHOT
  3. 11.8.3 OPERATING BUSINESS SEGMENTS
  4. 11.8.4 PRODUCT PORTFOLIO
  5. 11.8.5 BUSINESS PERFORMANCE
  6. 11.8.6 BUSINESS SEGMENTS
  7. 11.8.7 GEOGRAPHIC SEGMENTS
  8. 11.8.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.8.9 PRIMARY MARKET COMPETITORS
17. 11.9 QIAGEN N.V.
18. 1. 11.9.1 COMPANY OVERVIEW
  2. 11.9.2 COMPANY SNAPSHOT
  3. 11.9.3 OPERATING BUSINESS SEGMENTS
  4. 11.9.4 PRODUCT PORTFOLIO
  5. 11.9.5 BUSINESS PERFORMANCE
  6. 11.9.6 BUSINESS SEGMENTS
  7. 11.9.7 GEOGRAPHIC SEGMENTS
  8. 11.9.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.9.9 PRIMARY MARKET COMPETITORS
19. 11.10 BIO-RAD LABORATORIES, INC.
20. 1. 11.10.1 COMPANY OVERVIEW
  2. 11.10.2 COMPANY SNAPSHOT
  3. 11.10.3 OPERATING BUSINESS SEGMENTS
  4. 11.10.4 PRODUCT PORTFOLIO
  5. 11.10.5 BUSINESS PERFORMANCE
  6. 11.10.6 BUSINESS SEGMENTS
  7. 11.10.7 GEOGRAPHIC SEGMENTS
  8. 11.10.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.10.9 PRIMARY MARKET COMPETITORS

TABLE 1. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 2. REAGENTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 3. INSTRUMENTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 4. SOFTWARE AND SERVICES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 5. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 6. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 7. RAPID TESTS, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 8. CHEMILUMINESCENCE IMMUNOASSAY (CLIA), MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 9. ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT), MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 10. RADIOIMMUNOASSAY (RIA), MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 11. WESTERN BLOT, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 12. IMMUNODIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 13. HEMATOLOGY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 14. PCR, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 15. INAAT, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 16. HYBRIDIZATION, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 17. DNA DIAGNOSTICS, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 18. MICROARRAY, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 19. OTHER MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 20. MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 21. TISSUE DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 22. BASIC METABOLIC PANEL, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 23. LIVER PANEL, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 24. RENAL PROFILE, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 25. LIPID PROFILE, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 26. THYROID FUNCTION PANEL, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 27. ELECTROLYTE PANEL, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 28. SPECIALITY CHEMICALS, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 29. CLINICAL CHEMISTRY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 30. OTHER IVD TECHNIQUES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 31. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 32. INFECTIOUS DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 33. CANCER, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 34. CARDIAC DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 35. IMMUNE SYSTEM DISORDERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 36. NEPHROLOGICAL DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 37. GASTROINTESTINAL DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 38. OTHERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 39. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 40. STAND ALONE LABORATORY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 41. HOSPITALS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 42. ACADEMICS AND MEDICAL SCHOOLS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 43. POINT OF CARE TESTING, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 44. OTHER END USERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 45. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 46. AUSTRALIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 47. AUSTRALIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 48. AUSTRALIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 49. AUSTRALIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 50. CHINA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 51. CHINA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 52. CHINA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 53. CHINA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 54. INDIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 55. INDIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 56. INDIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 57. INDIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 58. JAPAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 59. JAPAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 60. JAPAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 61. JAPAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 62. SOUTH KOREA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 63. SOUTH KOREA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 64. SOUTH KOREA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 65. SOUTH KOREA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 66. INDONESIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 67. INDONESIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 68. INDONESIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 69. INDONESIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 70. SINGAPORE ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 71. SINGAPORE ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 72. SINGAPORE ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 73. SINGAPORE ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 74. TAIWAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 75. TAIWAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 76. TAIWAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 77. TAIWAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 78. THAILAND ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 79. THAILAND ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 80. THAILAND ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 81. THAILAND ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 82. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 83. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 84. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 85. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 86. ROCHE HOLDING AG: COMPANY SNAPSHOT
TABLE 87. ROCHE HOLDING AG: OPERATING BUSINESS SEGMENTS
TABLE 88. ROCHE HOLDING AG: PRODUCT PORTFOLIO
TABLE 89. ROCHE HOLDING AG: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 90. ROCHE HOLDING AG: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 91. ROCHE HOLDING AG: KEY STRATERGY
TABLE 92. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 93. ABBOTT LABORATORIES: OPERATING BUSINESS SEGMENTS
TABLE 94. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 95. ABBOTT LABORATORIES: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 96. ABBOTT LABORATORIES: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 97. ABBOTT LABORATORIES: KEY STRATERGY
TABLE 98. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 99. THERMO FISHER SCIENTIFIC INC.: OPERATING BUSINESS SEGMENTS
TABLE 100. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 101. THERMO FISHER SCIENTIFIC INC.: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 102. THERMO FISHER SCIENTIFIC INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 103. THERMO FISHER SCIENTIFIC INC.: KEY STRATERGY
TABLE 104. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 105. DANAHER CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 106. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 107. DANAHER CORPORATION: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 108. DANAHER CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 109. DANAHER CORPORATION: KEY STRATERGY
TABLE 110. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
TABLE 111. BECTON, DICKINSON AND COMPANY: OPERATING BUSINESS SEGMENTS
TABLE 112. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
TABLE 113. BECTON, DICKINSON AND COMPANY: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 114. BECTON, DICKINSON AND COMPANY: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 115. BECTON, DICKINSON AND COMPANY: KEY STRATERGY
TABLE 116. SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
TABLE 117. SIEMENS HEALTHINEERS AG: OPERATING BUSINESS SEGMENTS
TABLE 118. SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO
TABLE 119. SIEMENS HEALTHINEERS AG: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 120. SIEMENS HEALTHINEERS AG: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 121. SIEMENS HEALTHINEERS AG: KEY STRATERGY
TABLE 122. BIOMéRIEUX SA: COMPANY SNAPSHOT
TABLE 123. BIOMéRIEUX SA: OPERATING BUSINESS SEGMENTS
TABLE 124. BIOMéRIEUX SA: PRODUCT PORTFOLIO
TABLE 125. BIOMéRIEUX SA: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 126. BIOMéRIEUX SA: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 127. BIOMéRIEUX SA: KEY STRATERGY
TABLE 128. SYSMEX CORPORATION: COMPANY SNAPSHOT
TABLE 129. SYSMEX CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 130. SYSMEX CORPORATION: PRODUCT PORTFOLIO
TABLE 131. SYSMEX CORPORATION: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 132. SYSMEX CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 133. SYSMEX CORPORATION: KEY STRATERGY
TABLE 134. QIAGEN N.V.: COMPANY SNAPSHOT
TABLE 135. QIAGEN N.V.: OPERATING BUSINESS SEGMENTS
TABLE 136. QIAGEN N.V.: PRODUCT PORTFOLIO
TABLE 137. QIAGEN N.V.: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 138. QIAGEN N.V.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 139. QIAGEN N.V.: KEY STRATERGY
TABLE 140. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 141. BIO-RAD LABORATORIES, INC.: OPERATING BUSINESS SEGMENTS
TABLE 142. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 143. BIO-RAD LABORATORIES, INC.: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 144. BIO-RAD LABORATORIES, INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 145. BIO-RAD LABORATORIES, INC.: KEY STRATERGY

FIGURE 1. BARGAINING POWER OF SUPPLIERS
FIGURE 2. BARGAINING POWER OF BUYERS
FIGURE 3. DEGREE OF COMPETITION
FIGURE 4. THREAT OF SUBSTITUTE
FIGURE 5. THREAT OF NEW ENTRANTS
FIGURE 6. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
FIGURE 7. REAGENTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 8. INSTRUMENTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 9. SOFTWARE AND SERVICES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 10. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
FIGURE 11. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 12. RAPID TESTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 13. CHEMILUMINESCENCE IMMUNOASSAY (CLIA), MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 14. ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT), MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 15. RADIOIMMUNOASSAY (RIA), MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 16. WESTERN BLOT, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 17. IMMUNODIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 18. HEMATOLOGY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 19. PCR, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 20. INAAT, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 21. HYBRIDIZATION, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 22. DNA DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 23. MICROARRAY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 24. OTHER MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 25. MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 26. TISSUE DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 27. BASIC METABOLIC PANEL, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 28. LIVER PANEL, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 29. RENAL PROFILE, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 30. LIPID PROFILE, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 31. THYROID FUNCTION PANEL, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 32. ELECTROLYTE PANEL, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 33. SPECIALITY CHEMICALS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 34. CLINICAL CHEMISTRY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 35. OTHER IVD TECHNIQUES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 36. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
FIGURE 37. INFECTIOUS DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 38. CANCER, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 39. CARDIAC DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 40. IMMUNE SYSTEM DISORDERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 41. NEPHROLOGICAL DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 42. GASTROINTESTINAL DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 43. OTHERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 44. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
FIGURE 45. STAND ALONE LABORATORY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 46. HOSPITALS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 47. ACADEMICS AND MEDICAL SCHOOLS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 48. POINT OF CARE TESTING, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 49. OTHER END USERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 50. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY REGION 2023-2030, (MILLION USD)
FIGURE 51. AUSTRALIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 52. AUSTRALIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 53. AUSTRALIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 54. AUSTRALIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 55. CHINA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 56. CHINA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 57. CHINA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 58. CHINA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 59. INDIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 60. INDIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 61. INDIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 62. INDIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 63. JAPAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 64. JAPAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 65. JAPAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 66. JAPAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 67. SOUTH KOREA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 68. SOUTH KOREA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 69. SOUTH KOREA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 70. SOUTH KOREA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 71. INDONESIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 72. INDONESIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 73. INDONESIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 74. INDONESIA ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 75. SINGAPORE ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 76. SINGAPORE ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 77. SINGAPORE ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 78. SINGAPORE ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 79. TAIWAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 80. TAIWAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 81. TAIWAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 82. TAIWAN ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 83. THAILAND ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 84. THAILAND ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 85. THAILAND ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 86. THAILAND ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 87. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 88. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 89. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 90. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 91. ROCHE HOLDING AG: NET SALES, (2021-2023)
FIGURE 92. ROCHE HOLDING AG: PRIMARY MARKET COMPETITORS
FIGURE 93. ABBOTT LABORATORIES: NET SALES, (2021-2023)
FIGURE 94. ABBOTT LABORATORIES: PRIMARY MARKET COMPETITORS
FIGURE 95. THERMO FISHER SCIENTIFIC INC.: NET SALES, (2021-2023)
FIGURE 96. THERMO FISHER SCIENTIFIC INC.: PRIMARY MARKET COMPETITORS
FIGURE 97. DANAHER CORPORATION: NET SALES, (2021-2023)
FIGURE 98. DANAHER CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 99. BECTON, DICKINSON AND COMPANY: NET SALES, (2021-2023)
FIGURE 100. BECTON, DICKINSON AND COMPANY: PRIMARY MARKET COMPETITORS
FIGURE 101. SIEMENS HEALTHINEERS AG: NET SALES, (2021-2023)
FIGURE 102. SIEMENS HEALTHINEERS AG: PRIMARY MARKET COMPETITORS
FIGURE 103. BIOMéRIEUX SA: NET SALES, (2021-2023)
FIGURE 104. BIOMéRIEUX SA: PRIMARY MARKET COMPETITORS
FIGURE 105. SYSMEX CORPORATION: NET SALES, (2021-2023)
FIGURE 106. SYSMEX CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 107. QIAGEN N.V.: NET SALES, (2021-2023)
FIGURE 108. QIAGEN N.V.: PRIMARY MARKET COMPETITORS
FIGURE 109. BIO-RAD LABORATORIES, INC.: NET SALES, (2021-2023)
FIGURE 110. BIO-RAD LABORATORIES, INC.: PRIMARY MARKET COMPETITORS

At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.

Research Landscape

We navigate the world of research with two primary approaches:

Qualitative Approach

Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.

Quantitative Research

In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.

Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.

Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.

Our Specialized Toolbox for Industry-Specific Market Research

We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:

Information Procurement

The stage entails acquiring market data or relevant information through various sources and methodologies.

Market Research Approach

We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.

Porters Five Forces Analysis

We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.

SWOT Analysis

Forecasting

We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.

Frequently Asked Questions

The Asia-Pacific in-vitro diagnostics market revenue was valued at USD 27.51 billion in 2023 and is projected to grow at a size of CAGR of 5.4%, reaching up to USD 40.79 billion by 2030.

The key players in the Asia-Pacific in-vitro diagnostics market include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.

Germany holds the largest share of the Asia-Pacific in-vitro diagnostics industry, owing to prevalence of chronic diseases.

High costs associated with research, development, and regulatory approval are significant factors restraining the Asia-Pacific IVD market growth.

Introduction of Point-of-Care Testing (POCT) solutions create opportunities for the Asia-Pacific in-vitro diagnostics market in the coming future.

Download Free Sample

Full Name *

Please Enter Full Name

Business Email Id *

Please Enter Valid Email ID

Phone Number *

Please enter Country Code and Phone No

Message

Please enter message

Yes, I have read the Privacy Policy

Purchase Options Flash
sale

Multi User

$3,917 $5595

Single User

$3,217 $4595

Enterprise

$5,317 $7595

Datapack

$1,817 $2595

Download Sample

Inquire Before Buying